Gain Therapeutics (GANX) Invested Capital (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Invested Capital of $100281.0 for Q1 2026, down 11.35% year-over-year from $113121.0 in Q1 2025, and down 0.58% quarter-over-quarter from $100869.0 in Q4 2025.
Gain Therapeutics (GANX) Invested Capital (2020 - 2026) Analysis & Trends
Gain Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $100281.0 for Q1 2026.
- In Q1 2026, Invested Capital fell 11.35% year-over-year to $100281.0; the TTM figure through Mar 2026 stood at $452803.0 (changed 0.04% YoY), while the FY2025 annual figure was $100869.0, down 8.45% from the prior year.
- Invested Capital for Q1 2026 stood at $100281.0, down from $100869.0 in the prior quarter.
- The five-year high for Invested Capital was $126108.0 in Q2 2025, with the low at $83747.0 in Q2 2022.
- The 5-year median for Invested Capital is $110177.0 (2024), against an average of $108527.1.
- The sharpest annual moves came in 2022 and 2026: Invested Capital surged 95.6% in 2022, then dropped 11.35% in 2026.
- Gain Therapeutics' Invested Capital stood at $108135.0 in 2022, then gained by 9.86% to $118797.0 in 2023, then dropped by 7.26% to $110177.0 in 2024, then retreated by 8.45% to $100869.0 in 2025, then declined by 0.58% to $100281.0 in 2026.
- Business Quant data shows GANX's Invested Capital at $100281.0 in Q1 2026, $100869.0 in Q4 2025, and $125545.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | 123,628.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123,628.00 |
| Mar 31, 2026 | 100,281.00 |
| Dec 31, 2025 | 100,869.00 |
| Sep 30, 2025 | 125,545.00 |
| Jun 30, 2025 | 126,108.00 |
| Mar 31, 2025 | 113,121.00 |
| Dec 31, 2024 | 110,177.00 |
| Sep 30, 2024 | 118,280.00 |
| Jun 30, 2024 | 111,051.00 |
| Mar 31, 2024 | 110,848.00 |
| Dec 31, 2023 | 118,797.00 |
| Sep 30, 2023 | 109,281.00 |
| Jun 30, 2023 | 111,636.00 |
| Mar 31, 2023 | 109,200.00 |
| Dec 31, 2022 | 108,135.00 |
| Sep 30, 2022 | 101,260.00 |
| Jun 30, 2022 | 83,747.00 |
| Mar 31, 2022 | 86,624.00 |
| Dec 31, 2021 | 103,826.00 |
| Sep 30, 2021 | 86,645.00 |